These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 29103264)

  • 1. Suppressors for Human Epidermal Growth Factor Receptor 2/4 (HER2/4): A New Family of Anti-Toxoplasmic Agents in ARPE-19 Cells.
    Kim YH; Bhatt L; Ahn HJ; Yang Z; Lee WK; Nam HW
    Korean J Parasitol; 2017 Oct; 55(5):491-503. PubMed ID: 29103264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Afatinib Reduces STAT6 Signaling of Host ARPE-19 Cells Infected with Toxoplasma gondii.
    Yang Z; Ahn HJ; Park YH; Nam HW
    Korean J Parasitol; 2016 Feb; 54(1):31-8. PubMed ID: 26951976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential action of small molecule HER kinase inhibitors on receptor heterodimerization: therapeutic implications.
    Sánchez-Martín M; Pandiella A
    Int J Cancer; 2012 Jul; 131(1):244-52. PubMed ID: 21826647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tyrosine kinase inhibitors as modulators of trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity in breast cancer cell lines.
    Collins DM; Gately K; Hughes C; Edwards C; Davies A; Madden SF; O'Byrne KJ; O'Donovan N; Crown J
    Cell Immunol; 2017 Sep; 319():35-42. PubMed ID: 28735814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Secretome Analysis of Host Cells Infected with Toxoplasma gondii after Treatment of Human Epidermal Growth Factor Receptor 2/4 Inhibitors.
    Kim HJ; Ahn HJ; Kang H; Park J; Oh SG; Choi S; Lee WK; Nam HW
    Korean J Parasitol; 2020 Jun; 58(3):249-255. PubMed ID: 32615738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gefitinib inhibits the growth of Toxoplasma gondii in HeLa cells.
    Yang Z; Ahn HJ; Nam HW
    Korean J Parasitol; 2014 Aug; 52(4):439-41. PubMed ID: 25246725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A gene expression profile indicative of early stage HER2 targeted therapy response.
    O'Neill F; Madden SF; Clynes M; Crown J; Doolan P; Aherne ST; O'Connor R
    Mol Cancer; 2013 Jul; 12():69. PubMed ID: 23816254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interaction between parasitophorous vacuolar membrane-associated GRA3 and calcium modulating ligand of host cell endoplasmic reticulum in the parasitism of Toxoplasma gondii.
    Kim JY; Ahn HJ; Ryu KJ; Nam HW
    Korean J Parasitol; 2008 Dec; 46(4):209-16. PubMed ID: 19127325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apoptosis-related molecular differences for response to tyrosin kinase inhibitors in drug-sensitive and drug-resistant human bladder cancer cells.
    Li J; Lv B; Li X; He Z; Zhou K
    J Cancer Res Ther; 2013; 9(4):668-71. PubMed ID: 24518715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?
    Ou SH; Soo RA
    Drug Des Devel Ther; 2015; 9():5641-53. PubMed ID: 26508839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative analysis of drug response and gene profiling of HER2-targeted tyrosine kinase inhibitors.
    Conlon NT; Kooijman JJ; van Gerwen SJC; Mulder WR; Zaman GJR; Diala I; Eli LD; Lalani AS; Crown J; Collins DM
    Br J Cancer; 2021 Mar; 124(7):1249-1259. PubMed ID: 33473169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs.
    Kobayashi Y; Togashi Y; Yatabe Y; Mizuuchi H; Jangchul P; Kondo C; Shimoji M; Sato K; Suda K; Tomizawa K; Takemoto T; Hida T; Nishio K; Mitsudomi T
    Clin Cancer Res; 2015 Dec; 21(23):5305-13. PubMed ID: 26206867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis.
    Zhou Y; Li S; Hu YP; Wang J; Hauser J; Conway AN; Vinci MA; Humphrey L; Zborowska E; Willson JK; Brattain MG
    Cancer Res; 2006 Jan; 66(1):404-11. PubMed ID: 16397255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors.
    Wang SE; Narasanna A; Perez-Torres M; Xiang B; Wu FY; Yang S; Carpenter G; Gazdar AF; Muthuswamy SK; Arteaga CL
    Cancer Cell; 2006 Jul; 10(1):25-38. PubMed ID: 16843263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer.
    Yonesaka K; Kudo K; Nishida S; Takahama T; Iwasa T; Yoshida T; Tanaka K; Takeda M; Kaneda H; Okamoto I; Nishio K; Nakagawa K
    Oncotarget; 2015 Oct; 6(32):33602-11. PubMed ID: 26418897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lapatinib, a dual inhibitor of EGFR and HER2, has synergistic effects with 5-fluorouracil on esophageal carcinoma.
    Guo XF; Zhu XF; Zhong GS; Deng BG; Gao ZT; Wang H
    Oncol Rep; 2012 May; 27(5):1639-45. PubMed ID: 22293713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of common epidermal growth factor receptor and HER2 variants on receptor activity and inhibition by lapatinib.
    Gilmer TM; Cable L; Alligood K; Rusnak D; Spehar G; Gallagher KT; Woldu E; Carter HL; Truesdale AT; Shewchuk L; Wood ER
    Cancer Res; 2008 Jan; 68(2):571-9. PubMed ID: 18199554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of MET activation in determining the sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors.
    Rho JK; Choi YJ; Lee JK; Ryoo BY; Na II; Yang SH; Lee SS; Kim CH; Yoo YD; Lee JC
    Mol Cancer Res; 2009 Oct; 7(10):1736-43. PubMed ID: 19808904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erlotinib directly inhibits HER2 kinase activation and downstream signaling events in intact cells lacking epidermal growth factor receptor expression.
    Schaefer G; Shao L; Totpal K; Akita RW
    Cancer Res; 2007 Feb; 67(3):1228-38. PubMed ID: 17283159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of the putative cancer stem cell markers and growth factor receptor expression on the sensitivity of ovarian cancer cells to treatment with various forms of small molecule tyrosine kinase inhibitors and cytotoxic drugs.
    Puvanenthiran S; Essapen S; Seddon AM; Modjtahedi H
    Int J Oncol; 2016 Nov; 49(5):1825-1838. PubMed ID: 27599579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.